Ask us a question
520 547-3440
info@c-path.org
Subscribe
Go to C-Path EU
Home
About
HOW WE OPERATE
Breadth of Expertise
Timeline
People
FAQ
Employment
Annual Reports
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS
BmDR
Biomarker Data Repository
CPAD
Critical Path for Alzheimer’s Disease
CPP
Critical Path for Parkinson’s
CP-SCD
Critical Path for Sickle Cell Disease
CPTR
Critical Path to TB Drug Regimens
CPTA
Critical Path to Therapeutics for the Ataxias
CDRC
CURE Drug Repurposing Collaboratory
DCC
Data Collaboration Center
D-RSC
Duchenne Regulatory Science Consortium
eCOA Consortium
Electronic Clinical Outcome Assessment Consortium
FA-ICD
Friedreich’s Ataxia Integrated Clinical Database
HD-RSC
Huntington’s Disease Regulatory Science Consortium
INC
International Neonatal Consortium
MSOAC
Multiple Sclerosis Outcome Assessments Consortium
PRO Consortium
Patient-Reported
Outcome Consortium
PKDOC
Polycystic Kidney Disease Outcomes Consortium
PredicTox KE
PredicTox Knowledge Environment
PSTC
Predictive Safety Testing Consortium
QuantMed
Quantitative Medicine Program
RDCA-DAP
Rare Disease Cures Accelerator-Data and Analytics Platform
RD-COA Consortium
Rare Disease Clinical Outcome Assessment Consortium
TB-PACTS
TB-Platform for Aggregation of Clinical TB Studies
TTC
Transplant Therapeutics Consortium
TOMI-T1D
Trial Outcome Markers Initiative in T1D Consortium
T1D
Type 1 Diabetes Consortium
Completed Consortia
CFAST
Coalition for Accelerating Standards & Therapies
PTC
Pediatric Trials Consortium
Core Competencies
Evidentiary Considerations
Impact
Impact Stories
Successes
News & Events
Events
News
Videos
Publications
Presentations
Press Releases
Education
Contact
Donate
News
Home
>
News & Events
>
Publications
>
C-Path
>
Charting A Path Toward Combination Therapy For Alzheimer’s Disease
86,57,60
News
January 1, 2015
PRINT
PDF
Charting A Path Toward Combination Therapy For Alzheimer’s Disease
Related Posts
Building A Roadmap For Developing Combination Therapies For Alzheimer’s Disease
x
